Description_x000D_ Application_x000D_ Axitinib has been used as a vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor (TKI) to study its effect on renal cancer cell proliferation in vitro. It has also been used to inhibit anterior mesenteric artery (AMA) angiogenesis in dechlorinated embryos maintained in conditioned water (CW)._x000D_ Packaging_x000D_ 5 mg in glass bottle_x000D_ Biochem/physiol Actions_x000D_ Axitinib (AG-013736) is an orally available, potent (picomolar) and selective tyrosine kinase inhibitor that blocks VEGF receptors 1, 2 and 3. The drug blocks VEGF-mediated endothelial cell survival, tube formation, and downstream signaling through endothelial nitric oxide synthase, Akt and extracellular signal-regulated kinase._x000D_ Features and Benefits_x000D_ This compound is a featured product for Kinase Phosphatase Biology research. Click here to discover more featured Kinase Phosphatase Biology products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm._x000D_ This compound is also offered as part of Sigma′s Library of Pharmacologically Active Compounds (LOPAC®Pfizer), a collection of 90 Pfizer-developed drugs and research tools. Click here to learn more._x000D_ Other Notes_x000D_ This compound was developed by Pfizer for Kinase Phosphatase Biology research. To learn more about Sigma′s partnership with Pfizer and view other authentic, high-quality Pfizer compounds, visit sigma.com/bsm-pfizer._x000D_ To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here._x000D_ Legal Information_x000D_ Sold for research purposes under agreement from Pfizer Inc._x000D_ LOPAC is a registered trademark of Sigma-Aldrich Co. LLC_x000D_ Pfizer is a registered trademark of Pfizer, Inc.